中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2012年
3期
325-326
,共2页
黄可青%郑晓辉%王光丽%庄见齐
黃可青%鄭曉輝%王光麗%莊見齊
황가청%정효휘%왕광려%장견제
非诺贝特%非酒精性脂肪肝
非諾貝特%非酒精性脂肪肝
비낙패특%비주정성지방간
Fenofibrate%Non-alcoholic fatty liver
目的 比较非诺贝特与多烯磷脂酰胆碱治疗非酒精性脂肪肝(NAFLD)的临床疗效.方法 将86例非酒精性脂肪肝患者随机分为治疗组(45例)和对照组(41例).治疗组给予非诺贝特0.2g,每天1次,对照组给予多烯磷脂酰胆碱(易善复)456 mg,每天3次,疗程均为12周.观察两组患者治疗前后的肝功能、血脂、临床症状及肝脏B超检查结果变化,比较两组的疗效.结果 治疗组症状改善率、肝功能及血脂复常率、肝脏超声影像学改善明显优于对照组.治疗组与对照组有效率分别为82.2%( 37/45)、63.4%( 26/41),差异有统计学意义(x2=3.874,P<0.05).结论 非诺贝特治疗非酒精性脂肪肝疗效好,且药品费用较低,无明显不良反应,值得推广应用.
目的 比較非諾貝特與多烯燐脂酰膽堿治療非酒精性脂肪肝(NAFLD)的臨床療效.方法 將86例非酒精性脂肪肝患者隨機分為治療組(45例)和對照組(41例).治療組給予非諾貝特0.2g,每天1次,對照組給予多烯燐脂酰膽堿(易善複)456 mg,每天3次,療程均為12週.觀察兩組患者治療前後的肝功能、血脂、臨床癥狀及肝髒B超檢查結果變化,比較兩組的療效.結果 治療組癥狀改善率、肝功能及血脂複常率、肝髒超聲影像學改善明顯優于對照組.治療組與對照組有效率分彆為82.2%( 37/45)、63.4%( 26/41),差異有統計學意義(x2=3.874,P<0.05).結論 非諾貝特治療非酒精性脂肪肝療效好,且藥品費用較低,無明顯不良反應,值得推廣應用.
목적 비교비낙패특여다희린지선담감치료비주정성지방간(NAFLD)적림상료효.방법 장86례비주정성지방간환자수궤분위치료조(45례)화대조조(41례).치료조급여비낙패특0.2g,매천1차,대조조급여다희린지선담감(역선복)456 mg,매천3차,료정균위12주.관찰량조환자치료전후적간공능、혈지、림상증상급간장B초검사결과변화,비교량조적료효.결과 치료조증상개선솔、간공능급혈지복상솔、간장초성영상학개선명현우우대조조.치료조여대조조유효솔분별위82.2%( 37/45)、63.4%( 26/41),차이유통계학의의(x2=3.874,P<0.05).결론 비낙패특치료비주정성지방간료효호,차약품비용교저,무명현불량반응,치득추엄응용.
Objective To investigate the clinical effects of fenofibrate and polyene phosphatidylcholine in treatment of non-alcoholic fatty liver disease.Methods 86 patients with non-alcoholic fatty liver disease were randomly divided into two groups.45 cases in therapy group received 0.2g of fenofibrate once a day,and the others in control group received 456mg of polyene phosphatidylcholine for three times per day.All of the patients were treated for 12 weeks.Liver function,blood fat,clinical effect and liver B ultrasonic were analyzed before treatment and after 12 weeks.Results The improvement of liver function,blood fat,and liver ultrasonic imaging in therapy group was better than that in the control group.The cure rate was 82.2% in therapy group and 63.4% in control group.There was a statistical significance between the two groups ( x2 =3.874,P < 0.05).Conclusion Fenofibrate had significant therapeutic effect in treatment of non-alcoholic fatty liver disease with lower costs and lower side effects.